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Second-Line Combination Chemotherapy with Docetaxel
and Nedaplatin for Cisplatin-Pretreated Refractory
Metastatic/Recurrent Esophageal Squamous
Cell Carcinoma
Jianhua Jin, MD,* Xiyuan Xu, MD,† Fang Wang, MD,* Guodu Yan, MD,* Jianyue Liu, MD,‡
Wenbin Lu, MD,* Xianwen Li, MD,* Steven Jay Tucker, MD,§ Baoliang Zhong, MD,
Zhigang Cao, MD,¶ and Daoyuan Wang, MD#
Background: There is an urgent need for an effective second-line
chemotherapy regimen after failure of the standard cisplatin and
5-fluorouracil therapy.
Patients and Methods: This study investigated the efficacy and
toxicity of the combination of docetaxel (30 mg/m2) during a 1-hour
infusion, followed by nedaplatin (50 mg/m2) during a 2-hour infu-
sion (both drugs were administered on day 1 as an outpatient
regimen and repeated every 2 weeks) as second-line chemotherapy
for patients with cisplatin-pretreated refractory metastatic/recurrent
esophageal squamous cell carcinoma after surgery.
Results: Forty-six of the 48 patients (95.8%) were assessable for
response. Partial response was confirmed in 13 of 48 cases yielding
a response rate of 27.1% (95% confidence interval [CI], 14.5–
39.7%). The median overall time to progression and overall survival
was 3.1 months (95% CI, 2.3–3.9 months) and 5.9 months (95% CI,
3.9–7.8 months), respectively. The estimate of overall survival at 12
months was 16.7% (95% CI, 6.1–27.2%). Grade 3 anemia leucope-
nia, grade 4 anemia leucopenia and neutropenia were detected in
only 4 (8.7%), 8 (17.4%), and 9 patients (19.6%), respectively.
Conclusions: The combination chemotherapy of docetaxel and
nedaplatin in the outpatient setting is well tolerated and useful as
second-line chemotherapy for cisplatin-pretreated refractory meta-
static/recurrent esophageal squamous cell carcinoma.
Key Words: Esophageal squamous cell carcinoma, Docetaxel,
Nedaplatin, Salvage chemotherapy.
(J Thorac Oncol. 2009;4: 1017–1021)
Patients with esophageal cancer generally have a poorprognosis because the majority of them already have
locally unresectable or metastatic disease at presentation.
Furthermore, even after surgery with curative intent, local
recurrences and distant metastases are detected in approxi-
mately two thirds of the patients within 5 years of follow-up.1
Metastatic or recurrent esophageal cancer is an incurable
disease, and treatment outcomes for these patients are unsat-
isfactory because of the lack of effective therapies. Many
patients with esophageal cancer require palliative therapy to
treat symptoms, such as dysphagia. Chemotherapy is a pri-
mary option for the palliative treatment of metastatic or
recurrent disease. Accordingly, it is important to develop
effective and well-tolerated chemotherapeutic agents for
treatment. Currently, a combination of cisplatin with contin-
uous infusion of 5-fluorouracil (5-FU) is regarded as the
reference chemotherapy regimen for metastatic or recurrent
esophageal cancer, with a 30–40% response rate. However,
complete responses are rare, the median duration of response
is generally short (4–6 months), and the median survival is
only 6–10 months.2–7 Although a subset of patients with
metastatic or recurrent esophageal cancer initially responds to
this therapy, they ultimately experience a progression of
disease. A number of patients who progress following first-
line chemotherapy are still fit for second-line treatment.
However, there is no currently established salvage treatment
option.8 There is an urgent need for an effective second-line
chemotherapy regimen after failure of the standard cisplatin
and 5-FU therapy.
Docetaxel has shown extensive cytotoxic activity in
animal models and antitumor activity against various com-
mon cancers in clinical studies.9,10 Clinical trials of single-
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agent docetaxel have been reported in previously treated
patients with advanced esophageal cancer, with response
rates ranging from 16 to 28%.11,12 Nedaplatin (cis-diammine-
glycolatoplatinum) is a second generation platinum that does
not require hydration, several in vitro studies have demon-
strated that nedaplatin has equivalent antitumor activity to
cisplatin, with less nephrotoxity.13,14 Consistent with the
results of the in vitro studies, nedaplatin in combination with
other agents (e.g., docetaxel) has shown modest antitumor
activity for several human tumors (e.g., esophageal cancer),
with less nephrotoxicity and gastrointestinal toxicity.15–17
These reports prompted us to use a combination of docetaxel
with nedaplatin as a second-line regimen in patients with
advanced esophageal cancer because pretreated patients have
poorer tolerance to second-line chemotherapy, and a less
toxic treatment is desirable.
Accordingly, we investigated the efficacy and toxicity
of the combination of docetaxel and nedaplatin as second-line
chemotherapy for patients with cisplatin-pretreated refractory
metastatic/recurrent esophageal squamous cell carcinoma af-
ter surgery.
PATIENTS AND METHODS
Patient Eligibility
Eligibility criteria included histologically confirmed squa-
mous cell carcinoma of the esophagus, Eastern Cooperative
Oncology Group (ECOG) performance status of 0 to 2, and at
least one measurable disease(s) as assessed by RECIST. Inclu-
sion also required either disease progression after one or more
palliative chemotherapies of cisplatin-regimen or disease re-
currence within 12 months after neoadjuvant or adjuvant
chemotherapy of cisplatin-regimen. Patients had to have ade-
quate bone marrow (hemoglobin level9 g/dl, white blood cell
count 3000/mm3, neutrophil count 1500/mm3, and platelet
count 100,000/mm3), hepatic function (total bilirubin level
1.5 mg/dl and aspartate aminotransferase, alanine aminotrans-
ferase, and alkaline phosphatase levels 2.5 times the upper
limit of normal), and renal function (serum creatinine level
1.5 mg/dl). Minimum patient age was 18 years, and mini-
mum life expectancy was 12 weeks. Written informed con-
sent was obtained from all patients, and study was approved
by the local ethical committees.
Exclusion Criteria
Exclusion criteria included the following: adenocarcino-
mas of the esophagus including gastric-esophageal junction;
cerebral or leptomeningeal metastases; peripheral neuropathy
grade 2 by the National Cancer Institute Common Toxicity
Criteria; clinical hearing loss; active infection; active peptic
ulcer disease; uncontrolled diabetes mellitus; comorbidity
(congestive heart disease or angina, uncontrolled hyperten-
sion, arrhythmias, or myocardial infarction within the previ-
ous 6 months); disturbed mental state, concomitant malig-
nancy; pregnancy, lactation, or fertility (unless using
adequate contraceptives or barrier methods to prevent preg-
nancy) in women; and history of drug hypersensitivity.
Evaluation and Treatment
The primary end point of this study was response rate
(RR), and secondary objectives were toxicity, overall survival
(OS), and time to progression (TTP). All patients underwent
a baseline evaluation that included a physical examination
and a complete blood cell count with differential, serum
chemistry analysis, esophagography, an electrocardiograph,
and a computed tomography scan of the chest and other target
sites. Patients received 30 mg/m2 of docetaxel during a
1-hour infusion on day 1, followed by 50 mg/m2 of nedaplatin
during a 2-hour infusion on day 1 as an outpatient regimen
and repeated every 2 weeks for six cycles. These doses were
based on a phase I trial of chemotherapy using docetaxel and
nedaplatin in chemotherapy-naive patients with oral squa-
mous cell carcinoma15 and phase I/II study for unresectable
non-small cell lung cancer.18 That phase I trial recommended
60 mg/m2 docetaxel and 100 mg/m2 nedaplatin every 4 weeks
in chemotherapy-naive patients. Because our treatment was
to be repeated every 2 weeks in patients who had had prior
chemotherapy, we adjusted the doses of docetaxel and
nedaplatin to 30 and 50 mg/m2, respectively. Toxicities were
assessed according to National Cancer Institute Common
Toxicity Criteria (version 2.0) after each cycle. Patients were
excluded if they had unacceptable toxicity, progression of the
disease, or consent was withdrawn. Efficacy was evaluated
every 8 weeks (four cycles) by esophagography, computed
tomography scan, and/or magnetic resonance imaging. All
patients who achieved complete response or partial response
(PR), if applicable, continued this chemotherapy every 2
weeks as far as was possible.
Statistical Analysis
This trial used a two-stage optimal design as proposed
by Simon,19 with an 80% power to accept the hypothesis and
5% significance to reject the hypothesis. This trial was de-
signed to detect a RR of 40% when compared with a minimal,
clinically meaningful RR of 20%. Allowing for a follow-up
loss rate of 10%, the total sample size was 48 patients with
measurable disease. All enrolled patients were included in the
intention-to-treat analysis of efficacy. The duration of re-
sponse, TTP, and survival analyses were all estimated using
the Kaplan-Meier method.20 The duration of response was
defined as the interval from the onset of a complete response
or PR until evidence of disease progression was found.
Meanwhile, the TTP was calculated from the initiation of
chemotherapy to the date of disease progression, whereas OS
was measured from the initiation of chemotherapy to the date
of the last follow-up or death. The statistical data were
obtained using an SPSS software package (SPSS 11.5 Inc.,
Chicago, IL).
RESULTS
Patient Characteristics
From December 2004 to June 2006, a total of 48
patients were enrolled in this study from the Department of
Medical Oncology, Wujin Hospital, Medical School of
Jiangsu Unviersity. The characteristics of the patients are
summarized in Table 1. The median age was 55 years (range,
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28–73 years), with 35 men and 13 women. The majority of
the patients (85.4%) had ECOG performance status as either
0 or 1. Metastatic or recurrent sites in 33 cases (68.8%)
included distant lymph nodes. Liver and lung were the most
common organ sites of metastasis or recurrence (33.3 and
31.3%, respectively) at the time of initiation of DN (docetaxel
and nedaplatin) chemotherapy. Primary esophagectomy with
curative intent had been performed in all patients. Ten patients
(20.8%) received neoadjuvant chemotherapy, eight patients
(16.7%) received adjuvant chemotherapy, and 17 patients (35.4%)
received postoperative chemoradiotherapy. Initial therapy for
recurrence/metastases consisted of either 5-FU plus cisplatin
(70.8%) or capecitabine plus cisplatin (29.2%).
Response and Survival
Forty-six of the 48 patients (95.8%) were assessable for
response, of the two patients not assessable, both were lost to
follow-up after the first cycle of the treatment. All efficacy
data are reported using the intention-to-treat principle. PR
was confirmed in 13 of 48 cases yielding a RR of 27.1%
(95% confidence interval [CI], 14.5–39.7%). Of these 13
responses, six responses (46.2%) were observed after four
cycles, five responses (38.5%) after five cycles, and two
responses (15.4%) after six cycles (Table 2). The median
follow-up period was 12.6 months (range, 8.5–24.5 month).
The median overall TTP was 3.1 months (95% CI, 2.3–3.9
months). The estimated median OS was 5.9 months (95% CI,
3.9–7.8 months) (Figure 1). The estimate of OS at 12 months
was 16.7% (95% CI, 6.1–27.2%). The median duration of
response was 2.3 months (95% CI, 1.6–3.4 months).
Toxicity
Forty-seven patients (95.9%) were assessable for
safety. A total of 246 cycles of docetaxel and nedaplatin were
administered to the 46 patients, with the median number of
cycles administered per patient of six (range, 4–14 cycles).
Dose reduction was required in nine cycles (of 246), but no
delay in the start of chemotherapy was required. The treat-
ment was well tolerated and no toxic death occurred. The
most common toxic effects were anemia, leucopenia, neutro-
penia, nausea and vomiting, anorexia, and fatigue. Most
patients experienced anemia during their course of therapy
with 8.7% of patients (n 4) for grade 3/4 anemia, and grade
1 or 2 anemia was detected in 50% of patients (n  23).
Grade 3 leucopenia and neutropenia were documented in
eight patients (17.4%) and nine patients (17.4%), respec-
tively. Nausea and vomiting, anorexia, and fatigue were the
most common nonhematological toxicities. Grade 1/2 nausea
and vomiting, anorexia, and fatigue were observed in 15
FIGURE 1. Time to disease progression and overall survival
for all patients.
TABLE 2. Tumor Response (Intention-to-Treat Analysis,
n  48)
Response n (%)
CR 0
PR 13 (27.1)a
SD 18 (37.5)
PD 15 (31.3)
CR  PR  SD 31 (64.6)
Not assessable 2 (4.2)
a 95% confidential interval (CI)  14.5–39.7%.
CR, complete response; PR, partial response; SD, stable disease; PD, progressive
disease.
TABLE 1. Baseline Patient Characteristics (n  48)
Characteristics No. of Patients (%)
Age (yr)
Median (range) 55 (28–73)
Male/female 35/13
ECOG PS
0 10 (20.8)
1 31 (64.6)
2 7 (14.6)
Metastatic or recurrent sites
Lymph node 33 (68.8)
Liver 16 (33.3)
Lung 15 (31.3)
Pleura 11 (22.9)
Bone 5 (10.4)
Thyroid gland 4 (8.3)
Adrenal gland 3 (6.3)
Others 9 (18.8)
Primary therapy
Primary esophagectomy 48 (100.0)
Neoadjuvant chemotherapy 10 (20.8)
Adjuvant chemotherapy 8 (16.7)
Postoperative chemoradiotherapy 17 (35.4)
Initial therapy for recurrence/metastases
5-FU  cisplatin 34 (70.8)
Capecitabine  cisplatin 14 (29.2)
ECOG PS, Eastern Cooperative Oncology Group Performance Status; 5-FU,
5-fluorouracil.
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(32.6%), 22 (47.8%), and 19 patients (41.3%), respectively.
However, no grade 3/4 nonhematologic toxicity was ob-
served in this study. Two patients (4.3%) were hospitalized
because of treatment-related complications (one because of
infections, and another because of general weakness).
DISCUSSION
Although a survival advantage for chemotherapy over
best supportive care has already been demonstrated in gastric
cancer,21 it remains unproven for patients with esophageal
carcinoma. In this setting, the only two studies available had
a small number of patients with metastatic disease and
showed no significant benefit for the chemotherapy treatment
arm.22,23 However, patients undergoing radical esophagec-
tomy for esophageal cancer often relapse both locoregionally
and at distant sites despite curative intent. These patients
usually receive chemotherapy either alone or in combination
with radiotherapy. Cisplatin has been the key drug of choice
in most chemotherapy and chemoradiotherapy protocols. The
combination of cisplatin and 5-FU is the standard combina-
tion most frequently used in the treatment of esophageal
cancer worldwide.7 Although a subset of patients with met-
astatic or recurrent esophageal cancer initially responds to
this therapy, they ultimately experience a progression of
disease. There is an urgent need for an effective second-line
chemotherapy regimen after failure of the standard cisplatin
and 5-FU therapy.24–26
In this study, we investigated the efficacy and toxicity
of the combination of DN as second-line chemotherapy for
patients with cisplatin-pretreated refractory metastatic/recur-
rent esophageal squamous cell carcinoma after surgery, in the
outpatient setting. We designed this study in the outpatient
setting because this combination chemotherapy seemed to be
not only active but also favorable in keeping the quality of
life high. DN regimen showed a response rate of 27% with
the median TTP and OS of 3.1 and 5.9 months, and 1-year
survival rate was 16.7% in this study. Of the 13 responding
patients, eight patients survived 12 months or more. DN
seems to be a promising regimen as a second-line chemo-
therapy in cisplatin-pretreated refractory esophageal cancer.
There are two reports of a combination antitumor activity
with nedaplatin and docetaxel as second-line regimen for
advanced esophageal cancer in the previous studies.27,28 Ka-
nai et al. 28 did a retrospective analysis of 27 consecutive
patients treated with docetaxel and nedaplatin combination
therapy as a second-line regimen for advanced esophageal
cancer, found three of the 27 patients (11%) achieved PRs,
the disease control rate (PR  stable disease) was 52%, the
median OS was 11.4 months, and 1-year survival rate was
46.5%. Osaka et al.27 did a prospective study and reported
complete response, and PR were achieved by 3.6 and 35.7%
of 28 patients, and the median survival time and 1-year
survival rate were 8.5 months and 15.9%, respectively. The
results of this study can be comparable with the prospective
study by Osaka et al., even the median OS was lower than it,
as there was some difference of patient characteristics at the
baseline of between our study and others (e.g., 100% patients
had ECOG performance status either 0 or 1 as in study by
Osaka et al.27) The available data so far have shown only
modest activity in cisplatin-pretreated refractory esophageal
cancer; therefore, it is important to incorporate the new
targeted agents. Inhibition of the vascular endothelial growth
factor pathway is a promising approach for the treatment of a
variety of malignancies and may also benefit patients with
esophageal cancer.25
Grade 3 anemia leucopenia, grade 4 anemia leucopenia,
and neutropenia in only four (8.7%), eight (17.4%), and nine
(19.6%) patients, respectively, and no grade 3/4 nonhematologic
toxicity was observed in this study. These toxicities were well
tolerated. None of the patients were discontinued from the study
due to toxic effects. Osaka et al.27 evaluated the combination of
docetaxel and nedaplatin with decreased nephrotoxicity and
neurotoxicity compared with cisplatin and carboplatin in 28
patients with recurrent esophageal cancer. Nedaplatin is a
second-generation platinum complex with lower renal and
gastrointestinal toxicities than cisplatin. Kidney accumulation
of nedaplatin was lower than that of cisplatin, and nedaplatin
showed lower nephrotoxicities than cisplatin. In contrast to
cisplatin, nedaplatin does not require a large amount of fluid
infusion.29 There were no treatment-related deaths during this
study. Only two patients (4.3%) were hospitalized because of
treatment-related complications. In contrast, hospitalization
rates of other outpatient regimens for esophageal cancer were
reported to be much higher.30,31
In conclusion, this combination chemotherapy of do-
cetaxel and nedaplatin in the outpatient setting is well tolerated
and useful as second-line chemotherapy for cisplatin-pretreated
refractory metastatic/recurrent esophageal squamous cell carci-
noma. However, the development of more effective therapy is
warranted to improve the prognosis of esophageal cancer.
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